Lana Pine

Jeffrey Stark, MD, discusses the recent studies, BE BRIGHT, BE SURE, and BE VIVID, in which investigators analyzed the impact bimekizumab had on patients with psoriasis.

“Evidence has accumulated on the effectiveness of physical activity to reduce disease-related symptoms such as pain and comorbidity risk in people with rheumatoid arthritis,” investigators stated.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 15, 2021.

Approximately a third of systemic lupus erythematosus patients experience ocular involvement, which may be linked to disease pathophysiology.

Investigators analyzed the potential beneficial effect of hydroxychloroquine to prevent COVID-19 infection in patients with rheumatic disease.

“Considering medical appointments, laboratory tests, medications, and indirect costs, juvenile idiopathic arthritis generates elevated costs, which results in a high economic impact for the family,” investigators stated.

The post hoc analyses evaluated health-related quality of life and efficacy across 4 subgroups treated with either ixekizumab or adalimumab.

The Fast-Track Clinic reduced hospitalization rates for patients with polymyalgia rheumatica, which is helpful as symptoms of PMR can mimic other diseases, leading to hospitalization to rule out other conditions.

E Michael Lewiecki, MD, discusses his CCR West presentations entitled, “Controversies in Osteoporosis” and “What's New in Osteoporosis for 2021?”

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 8, 2021.

Veena Joy, MS, discusses Thermo Scientific’s recent FDA approval of their EliA SmDP-S test, which aides in the diagnosis of Systemic Lupus Erythematosus (SLE).

Test-retest reliability for Health Assessment Questionnaire–Disability Index and 36-item Short Form Health Survey physical functioning domain in patients with psoriatic arthritis was judged to be good and reasonable, respectively.

“Many patients with axial spondyloarthritis who receive treatment still experience disease-related burdens in different aspects of health-related quality of life,” investigators stated.

Few data exist for the use of golimumab in patients whose uveitis does not respond to adalimumab, a first-line biologic choice in refractory juvenile idiopathic arthritis-associated uveitis.

Sarah Stewart, PhD, discusses her study entitled "What Represents Treatment Efficacy in Long-term Studies of Gout Flare Prevention? An Interview Study of People With Gout."

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 1, 2021.

While telemedicine is a valuable tool to provide access to care for families seeking care within a small subspecialty with a limited supply of providers, there was a significantly lower amount of new pediatric patient visits in the beginning of the COVID-19 pandemic.

More patients with methotrexate intolerance receiving baricitinib 4 mg and adalimumab had no progression in radiographic progression at year 5 when compared with placebo.

Test your knowledge of the treatment and management of rheumatoid arthritis (RA) with our RA quizzes.

“Considering the fact that people with one and the same clinical condition can vary substantially in terms of disability, there is a need to expand the assessment tools,” investigators stated.

Catch up on Rheumatology Network's most recent highlights in rheumatoid arthritis news.

As genetics only play a small role in the risk of developing juvenile idiopathic arthritis, environmental factors, such as infections and antibiotic usage, are believed to be the main cause of the disease.

“In patients with rheumatoid arthritis, the prevalence of depression ranges between 14.8 and 22.5%, which is 2 to 3 times higher than in the general population,” investigators stated.

Jason Kolfenbach, MD, discusses his CCR West presentations entitled “Common Eye Disorders in Rheumatology Clinic” and “Top Secrets in Rheumatology.”

While the antioxidants in tea may reduce the risk of developing inflammatory diseases, such as rheumatoid arthritis, previous studies have shown inconclusive results.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending September 17, 2021.

Hyperuricemia is associated with vascular, cardiac, and renal disease, as well as gout. However, the reliability of a single measurement in defining hyperuricemia is unclear.

COVID-19 has added an additional level of complexity for patients with rheumatic disease who wish to become pregnant.

The efficacy evaluation of golimumab is crucial for patients with psoriatic arthritis, particularly for treating skin manifestations and psoriasis symptoms.

While lifestyle habits are modifiable risk factors, changing them can be especially challenging for patients with rheumatoid arthritis, who must also deal with chronic inflammatory disease.